Amgen strengthens rare disease drug portfolio with purchase of Horizon
A deal valued at $27.8 billion has been struck between Amgen and Horizon Therapeutics, wherein Amgen will buy the orphan drug manufacturer.
#rarediseases
Tag
ATMPs for rare diseases a priority for Innovative Health Initiative funding
Research themes under consideration for the next round of Innovative Health Initiative (IHI) funding include Topic 4: Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases.